Latest / Markets & Money News Today | 2 Min News | THE DAILY NOW!
Amgen Drug Combo Boosts Survival for Lung Cancer | Markets & Money News
Amgen's late-stage trial results reveal that their drug Imdelltra significantly reduces the risk of death by 58% when used alongside AstraZeneca's Imfinzi in patients with extensive-stage small cell lung cancer. The combination therapy extends overall survival to 21.1 months compared to 12.7 months with Imfinzi alone. Amgen's chief medical officer, Dr. Paul Burton, highlights this as a transformative development in treatment. With Imdelltra's sales rapidly increasing, this breakthrough has the
www.TheDailyNewsNow.com
This is an automated, high-level news summary based on public reporting and…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.